As of Aug 04
| +0.75 / +1.51%|
The 4 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 41.50, with a high estimate of 46.00 and a low estimate of 35.00. The median estimate represents a -17.58% decrease from the last price of 50.35.
The current consensus among 5 polled investment analysts is to Buy stock in Enanta Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.